Black Diamond Therapeutics, Inc. Profile Avatar - Palmy Investing

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic …

Biotechnology
US, Cambridge [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Black Diamond Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of BDTX's Analysis
CIK: 1701541 CUSIP: 09203E105 ISIN: US09203E1055 LEI: - UEI: -
Secondary Listings
BDTX has no secondary listings inside our databases.